Amicus Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Raised Its FY24 Revenue Growth Guidance.

Benzinga11/06 21:58

Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates

Zacks 11/06 20:35

Earnings Flash (FOLD) AMICUS THERAPEUTICS Reports Q3 EPS $0.10

MT Newswires11/06 20:09

Amicus Therapeutics Non-GAAP EPS of $0.10 Beats by $0.05, Revenue of $141.52M Beats by $6.56M

Seeking Alpha11/06 20:08

Amicus Therapeutics Raises FY24 Total Rev Growth Guidance to 30% - 32% >FOLD

Dow Jones11/06 20:01

Press Release: Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates

Dow Jones11/06 20:00